摘要
根据卫生部卫药发（１９９２）３５号文件，我们进行了开放、对照、多中心Ⅲ期临床研究，以探讨加贝酯对急性出血坏死性胰腺炎的疗效。共观察８５例，治疗组４９例，对照组３６例，我们发现：治疗组有效率为７４．２％，而对照组为３６．０％（Ｐ＜０．０５）；死亡率分别为４．１％与２２．２％（Ｐ＜０．０５）；两组在缓解症状、消退体征与血淀粉酶恢复正常的有效率分别为７５．４％、７１．８％与８１．６％以及３８．８％、３６．０％与４４．４％（Ｐ＜０．０５，三者均同），两组在缓解症状、消退体征与血淀粉酶恢复正常的时间分别为５．４１±２．３８、５．７６±２．３２与４．５８±２．３９以及７．１１±２．４７、７．５５±２．４８与７．５８±１．９５日（Ｐ＜０．０５三者均同）。治疗后血象、肝、肾功能无明显改变。以上表明：本品对急性出血坏死性胰腺炎的治疗安全可靠，有迅速缓解临床症状、降低死亡率与提高存活率之效。
In this paper,the open,random-matched multicenter trial was performed in order to study the efficacy of gabexate mesilate in treating the acute necrotic pancreatitis. Eighty-five patients were observed,including 49 cases of treat group and 36 cases of control group. As a result,the whole efficacy rates were 74. 2% in treat group and 36. 0% in control group (P<0. 05);the rate of death were 4. 1% and 22. 2% respectively (P<0. 05). The rate of sympton relief,sign disappearance and serum amylase recovery normality was 74. 4%, 71. 8% and 81. 6% respectively in treat group, but 38. 8%, 36. 0% and 44. 4% respectively in control group (P<0. 05, respectively). The duration of symptom relief,sign disappearance and serum amylase recovery normality was 5. 41±2. 38, 5. 67 ±2. 32 and 4. 58±2. 39 days respectively in treat group,but 7. 11 ± 2. 47, 7. 55 ±2. 48 and 7. 58± 1. 95 days respectively in control group (P<0. 05, respectively). There were no changes in blood rountine test,and hepatic and kidney function tests. Its suggest that gabexate mesilate can treat acute necrotic pancreatitis safely ,relieve the clinical features quickly ,decrease the death rates and increase the survival rates.
出处
《胃肠病学和肝病学杂志》
CAS
1995年第2期124-127,共4页
Chinese Journal of Gastroenterology and Hepatology
